^
BIOMARKER:

CXCL12-H

i
Other names: CXCL12, C-X-C Motif Chemokine Ligand 12, Stromal Cell-Derived Factor 1, PBSF, Pre-B Cell Growth-Stimulating Factor, Chemokine (C-X-C Motif) Ligand 12, Intercrine Reduced In Hepatomas, SCYB12, TPAR1, SDF1, IRH, C-X-C Motif Chemokine 12, CXCL12, SDF-1a, SDF-1b, TLSF-A, TLSF-B, HSDF-1, SDF1A, SDF1B, SDF-1, TLSF, HIRH
Entrez ID:
Related biomarkers:
8ms
Chemokine level predicts the therapeutic effect of anti-PD-1 antibody (nivolumab) therapy for malignant melanoma. (PubMed, Arch Dermatol Res)
Anti-programmed cell death protein 1 (PD-1) antibody drugs, nivolumab and pembrolizumab, are regarded as first-line therapies for advanced malignant melanoma. The patients with lower than average levels of CCL5 and CXCL12 had a large number of TILs (P = 0.04) and good disease-specific survival rate (P = 0.04). Therefore, CCL5 and CXCL12 could likely be used as biomarkers to predict the therapeutic effect of anti-PD-1 (nivolumab) therapy.
Journal • Tumor Mutational Burden • PD(L)-1 Biomarker • IO biomarker
|
TMB (Tumor Mutational Burden) • CD8 (cluster of differentiation 8) • CXCL12 (C-X-C Motif Chemokine Ligand 12)
|
CD8 positive • CXCL12-H
|
Keytruda (pembrolizumab) • Opdivo (nivolumab)
1year
Expression and prognostic value of CXCL12/CXCR4/CXCR7 axis in clear cell renal cell carcinoma. (PubMed, Clin Exp Nephrol)
Our data suggest that regarding overall survival, CXCL12 could be considered a valuable prognostic marker.
Journal
|
CXCR4 (Chemokine (C-X-C motif) receptor 4) • CXCL12 (C-X-C Motif Chemokine Ligand 12) • ACKR3 (Atypical Chemokine Receptor 3)
|
CXCL12-H
over1year
Prognostic Impact of CXCR7 and CXCL12 Expression in Patients with Esophageal Adenocarcinoma. (PubMed, Ann Surg Oncol)
High CXCR7 expression was associated with poor prognosis in patients with EAC, and high expression of CXCR7 with its ligand CXCL12 had a stronger association with prognosis. Further study of this potential biomarker using whole tissue samples and a larger sample size is warranted.
Clinical • Journal
|
CXCR4 (Chemokine (C-X-C motif) receptor 4) • CXCL12 (C-X-C Motif Chemokine Ligand 12)
|
CXCL12-H
over1year
CXCL12-mediated HOXB5 overexpression facilitates Colorectal Cancer metastasis through transactivating CXCR4 and ITGB3. (PubMed, Theranostics)
Furthermore, AMD3100, a specific CXCR4 inhibitor, significantly suppressed HOXB5-mediated CRC metastasis. HOXB5 expression was positively correlated with CXCR4 and ITGB3 expression in human CRC tissues, and patients with positive co-expression of HOXB5/CXCR4, or HOXB5/ITGB3 exhibited the worst prognosis. Our study implicates HOXB5 as a prognostic biomarker in CRC, and defines a CXCL12-HOXB5-CXCR4 positive feedback loop that plays an important role in promoting CRC metastasis.
Journal
|
CXCR4 (Chemokine (C-X-C motif) receptor 4) • CXCL12 (C-X-C Motif Chemokine Ligand 12) • ETS1 (ETS Proto-Oncogene 1)
|
CXCL12-H • CXCR4 positive
|
Mozobil (plerixafor)